Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 716

1.

A Glycolipid Adjuvant, 7DW8-5, Enhances the Protective Immune Response to the Current Split Influenza Vaccine in Mice.

Feng H, Nakajima N, Wu L, Yamashita M, Lopes TJS, Tsuji M, Hasegawa H, Watanabe T, Kawaoka Y.

Front Microbiol. 2019 Sep 18;10:2157. doi: 10.3389/fmicb.2019.02157. eCollection 2019.

2.

The Role of EGFR in Influenza Pathogenicity: Multiple Network-Based Approaches to Identify a Key Regulator of Non-lethal Infections.

Mitchell HD, Eisfeld AJ, Stratton KG, Heller NC, Bramer LM, Wen J, McDermott JE, Gralinski LE, Sims AC, Le MQ, Baric RS, Kawaoka Y, Waters KM.

Front Cell Dev Biol. 2019 Sep 20;7:200. doi: 10.3389/fcell.2019.00200. eCollection 2019.

3.

Influenza Virus Polymerase Mutation Stabilizes a Foreign Gene Inserted into the Virus Genome by Enhancing the Transcription/Replication Efficiency of the Modified Segment.

Furusawa Y, Yamada S, da Silva Lopes TJ, Dutta J, Khan Z, Kriti D, van Bakel H, Kawaoka Y.

MBio. 2019 Oct 1;10(5). pii: e01794-19. doi: 10.1128/mBio.01794-19.

4.

Food Additives as Novel Influenza Vaccine Adjuvants.

Feng H, Yamashita M, Wu L, Jose da Silva Lopes T, Watanabe T, Kawaoka Y.

Vaccines (Basel). 2019 Sep 24;7(4). pii: E127. doi: 10.3390/vaccines7040127.

5.

Soluble Recombinant Hemagglutinin Protein of H1N1pdm09 Influenza Virus Elicits Cross-Protection Against a Lethal H5N1 Challenge in Mice.

Yamada S, Yasuhara A, Kawaoka Y.

Front Microbiol. 2019 Sep 4;10:2031. doi: 10.3389/fmicb.2019.02031. eCollection 2019.

6.

Identification of a distinct lineage of aviadenovirus from crane feces.

Mukai Y, Tomita Y, Kryukov K, Nakagawa S, Ozawa M, Matsui T, Tomonaga K, Imanishi T, Kawaoka Y, Watanabe T, Horie M.

Virus Genes. 2019 Sep 23. doi: 10.1007/s11262-019-01703-w. [Epub ahead of print]

PMID:
31549291
7.

Neo-virology: The raison d'etre of viruses.

Watanabe T, Suzuki N, Tomonaga K, Sawa H, Matsuura Y, Kawaguchi Y, Takahashi H, Nagasaki K, Kawaoka Y.

Virus Res. 2019 Sep 11;274:197751. doi: 10.1016/j.virusres.2019.197751. [Epub ahead of print]

PMID:
31520652
8.

Long-term culture of human lung adenocarcinoma A549 cells enhances the replication of human influenza A viruses.

Ujie M, Takada K, Kiso M, Sakai-Tagawa Y, Ito M, Nakamura K, Watanabe S, Imai M, Kawaoka Y.

J Gen Virol. 2019 Oct;100(10):1345-1349. doi: 10.1099/jgv.0.001314.

PMID:
31424377
9.

Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys.

Arikata M, Itoh Y, Shichinohe S, Nakayama M, Ishigaki H, Kinoshita T, Le MQ, Kawaoka Y, Ogasawara K, Shimizu T.

Antiviral Res. 2019 Nov;171:104591. doi: 10.1016/j.antiviral.2019.104591. Epub 2019 Aug 14.

PMID:
31421167
10.

A Novel Vaccine Strategy to Overcome Poor Immunogenicity of Avian Influenza Vaccines through Mobilization of Memory CD4 T Cells Established by Seasonal Influenza.

DiPiazza AT, Fan S, Rattan A, DeDiego ML, Chaves F, Neumann G, Kawaoka Y, Sant AJ.

J Immunol. 2019 Sep 15;203(6):1502-1508. doi: 10.4049/jimmunol.1900819. Epub 2019 Aug 9.

PMID:
31399519
11.

Serological analysis of Ebola virus survivors and close contacts in Sierra Leone: A cross-sectional study.

Halfmann PJ, Eisfeld AJ, Watanabe T, Maemura T, Yamashita M, Fukuyama S, Armbrust T, Rozich I, N'jai A, Neumann G, Kawaoka Y, Sahr F.

PLoS Negl Trop Dis. 2019 Aug 1;13(8):e0007654. doi: 10.1371/journal.pntd.0007654. eCollection 2019 Aug.

12.

Effective mosaic-based nanovaccines against avian influenza in poultry.

Kingstad-Bakke BA, Chandrasekar SS, Phanse Y, Ross KA, Hatta M, Suresh M, Kawaoka Y, Osorio JE, Narasimhan B, Talaat AM.

Vaccine. 2019 Aug 14;37(35):5051-5058. doi: 10.1016/j.vaccine.2019.06.077. Epub 2019 Jul 9.

PMID:
31300285
13.

Isolation of Highly Pathogenic H5N1 Influenza Viruses in 2009-2013 in Vietnam.

Zhong G, Fan S, Lopes TJS, Le MQ, van Bakel H, Dutta J, Smith GJD, Jayakumar J, Nguyen HLK, Hoang PVM, Halfmann P, Hatta M, Su YCF, Neumann G, Kawaoka Y.

Front Microbiol. 2019 Jun 25;10:1411. doi: 10.3389/fmicb.2019.01411. eCollection 2019.

14.

Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice.

Moser MJ, Hatta Y, Gabaglia C, Sanchez A, Dias P, Sarawar S, Kawaoka Y, Hatta M, Neumann G, Bilsel P.

Vaccine. 2019 Jul 26;37(32):4533-4542. doi: 10.1016/j.vaccine.2019.06.043. Epub 2019 Jul 4.

15.

A single amino acid change in hemagglutinin reduces the cross-reactivity of antiserum against an equine influenza vaccine strain.

Nemoto M, Yamayoshi S, Bannai H, Tsujimura K, Kokado H, Kawaoka Y, Yamanaka T.

Arch Virol. 2019 Sep;164(9):2355-2358. doi: 10.1007/s00705-019-04328-4. Epub 2019 Jun 21.

PMID:
31227892
16.

Low Polymerase Activity Attributed to PA Drives the Acquisition of the PB2 E627K Mutation of H7N9 Avian Influenza Virus in Mammals.

Liang L, Jiang L, Li J, Zhao Q, Wang J, He X, Huang S, Wang Q, Zhao Y, Wang G, Sun N, Deng G, Shi J, Tian G, Zeng X, Jiang Y, Liu L, Liu J, Chen P, Bu Z, Kawaoka Y, Chen H, Li C.

MBio. 2019 Jun 18;10(3). pii: e01162-19. doi: 10.1128/mBio.01162-19.

17.

Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection.

Davis CW, Jackson KJL, McElroy AK, Halfmann P, Huang J, Chennareddy C, Piper AE, Leung Y, Albariño CG, Crozier I, Ellebedy AH, Sidney J, Sette A, Yu T, Nielsen SCA, Goff AJ, Spiropoulou CF, Saphire EO, Cavet G, Kawaoka Y, Mehta AK, Glass PJ, Boyd SD, Ahmed R.

Cell. 2019 May 30;177(6):1566-1582.e17. doi: 10.1016/j.cell.2019.04.036. Epub 2019 May 16.

PMID:
31104840
18.

A humanized MDCK cell line for the efficient isolation and propagation of human influenza viruses.

Takada K, Kawakami C, Fan S, Chiba S, Zhong G, Gu C, Shimizu K, Takasaki S, Sakai-Tagawa Y, Lopes TJS, Dutta J, Khan Z, Kriti D, van Bakel H, Yamada S, Watanabe T, Imai M, Kawaoka Y.

Nat Microbiol. 2019 Aug;4(8):1268-1273. doi: 10.1038/s41564-019-0433-6. Epub 2019 Apr 29.

PMID:
31036910
19.

Subclade 2.2.1-Specific Human Monoclonal Antibodies That Recognize an Epitope in Antigenic Site A of Influenza A(H5) Virus HA Detected between 2015 and 2018.

Okuda M, Yamayoshi S, Uraki R, Ito M, Hamabata T, Kawaoka Y.

Viruses. 2019 Apr 2;11(4). pii: E321. doi: 10.3390/v11040321.

20.

Identification of Amino Acid Residues in Influenza A Virus PA-X That Contribute to Enhanced Shutoff Activity.

Oishi K, Yamayoshi S, Kawaoka Y.

Front Microbiol. 2019 Mar 6;10:432. doi: 10.3389/fmicb.2019.00432. eCollection 2019.

21.

Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus.

Yasuhara A, Yamayoshi S, Kiso M, Sakai-Tagawa Y, Koga M, Adachi E, Kikuchi T, Wang IH, Yamada S, Kawaoka Y.

Nat Microbiol. 2019 Jun;4(6):1024-1034. doi: 10.1038/s41564-019-0401-1. Epub 2019 Mar 18.

PMID:
30886361
22.

Clinical significance of periosteal reaction as a predictive factor for treatment outcome of medication-related osteonecrosis of the jaw.

Kojima Y, Kawaoka Y, Sawada S, Hayashida S, Okuyama K, Yutori H, Kawakita A, Ishida S, Soutome S, Yanamoto S, Umeda M, Iwai H.

J Bone Miner Metab. 2019 Sep;37(5):913-919. doi: 10.1007/s00774-019-00994-1. Epub 2019 Mar 4.

PMID:
30830278
23.

Plasma lipidome reveals critical illness and recovery from human Ebola virus disease.

Kyle JE, Burnum-Johnson KE, Wendler JP, Eisfeld AJ, Halfmann PJ, Watanabe T, Sahr F, Smith RD, Kawaoka Y, Waters KM, Metz TO.

Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3919-3928. doi: 10.1073/pnas.1815356116. Epub 2019 Feb 11.

24.

Genetic and antigenic characterisation of influenza A(H3N2) viruses isolated in Yokohama during the 2016/17 and 2017/18 influenza seasons.

Kawakami C, Yamayoshi S, Akimoto M, Nakamura K, Miura H, Fujisaki S, Pattinson DJ, Shimizu K, Ozawa H, Momoki T, Saikusa M, Yasuhara A, Usuku S, Okubo I, Toyozawa T, Sugita S, Smith DJ, Watanabe S, Kawaoka Y.

Euro Surveill. 2019 Feb;24(6). doi: 10.2807/1560-7917.ES.2019.24.6.1800467.

25.

Characterization of Mouse Monoclonal Antibodies Against the HA of A(H7N9) Influenza Virus.

Ito M, Yamayoshi S, Murakami K, Saito K, Motojima A, Nakaishi K, Kawaoka Y.

Viruses. 2019 Feb 11;11(2). pii: E149. doi: 10.3390/v11020149.

26.

Host protein mimics viral protein to hinder infection by Ebola virus.

Yamayoshi S, Kawaoka Y.

Nature. 2019 Feb;566(7743):190-191. doi: 10.1038/d41586-019-00182-1. No abstract available.

PMID:
30737499
27.

Injectable Excipients as Novel Influenza Vaccine Adjuvants.

Feng H, Yamashita M, da Silva Lopes TJ, Watanabe T, Kawaoka Y.

Front Microbiol. 2019 Jan 24;10:19. doi: 10.3389/fmicb.2019.00019. eCollection 2019.

28.

Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.

Williamson LE, Flyak AI, Kose N, Bombardi R, Branchizio A, Reddy S, Davidson E, Doranz BJ, Fusco ML, Saphire EO, Halfmann PJ, Kawaoka Y, Piper AE, Glass PJ, Crowe JE Jr.

J Virol. 2019 Apr 3;93(8). pii: e01439-18. doi: 10.1128/JVI.01439-18. Print 2019 Apr 15.

29.

Predicting the Next Influenza Pandemics.

Neumann G, Kawaoka Y.

J Infect Dis. 2019 Apr 8;219(Supplement_1):S14-S20. doi: 10.1093/infdis/jiz040.

PMID:
30715371
30.

C57BL/6J and C57BL/6NJ Mice Are Differentially Susceptible to Inflammation-Associated Disease Caused by Influenza A Virus.

Eisfeld AJ, Gasper DJ, Suresh M, Kawaoka Y.

Front Microbiol. 2019 Jan 17;9:3307. doi: 10.3389/fmicb.2018.03307. eCollection 2018.

31.

Antibody-free digital influenza virus counting based on neuraminidase activity.

Tabata KV, Minagawa Y, Kawaguchi Y, Ono M, Moriizumi Y, Yamayoshi S, Fujioka Y, Ohba Y, Kawaoka Y, Noji H.

Sci Rep. 2019 Jan 31;9(1):1067. doi: 10.1038/s41598-018-37994-6.

32.

Current and future influenza vaccines.

Yamayoshi S, Kawaoka Y.

Nat Med. 2019 Feb;25(2):212-220. doi: 10.1038/s41591-018-0340-z. Epub 2019 Jan 28. Review.

PMID:
30692696
33.

Molecular Mechanism of Externalization of Phosphatidylserine on the Surface of Ebola Virus Particles.

Nanbo A, Kawaoka Y.

DNA Cell Biol. 2019 Feb;38(2):115-120. doi: 10.1089/dna.2018.4485. Epub 2019 Jan 7. Review.

PMID:
30615471
34.

Network-Guided Discovery of Influenza Virus Replication Host Factors.

Ackerman EE, Kawakami E, Katoh M, Watanabe T, Watanabe S, Tomita Y, Lopes TJ, Matsuoka Y, Kitano H, Shoemaker JE, Kawaoka Y.

MBio. 2018 Dec 18;9(6). pii: e02002-18. doi: 10.1128/mBio.02002-18.

35.

Glycosylation and an amino acid insertion in the head of hemagglutinin independently affect the antigenic properties of H5N1 avian influenza viruses.

Gu C, Zeng X, Song Y, Li Y, Liu L, Kawaoka Y, Zhao D, Chen H.

Sci China Life Sci. 2019 Jan;62(1):76-83. doi: 10.1007/s11427-018-9439-0. Epub 2018 Nov 30.

PMID:
30515728
36.

Isolation and Characterization of Human Monoclonal Antibodies That Recognize the Influenza A(H1N1)pdm09 Virus Hemagglutinin Receptor-Binding Site and Rarely Yield Escape Mutant Viruses.

Yasuhara A, Yamayoshi S, Ito M, Kiso M, Yamada S, Kawaoka Y.

Front Microbiol. 2018 Nov 1;9:2660. doi: 10.3389/fmicb.2018.02660. eCollection 2018.

37.

Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.

Hasegawa T, Hayashida S, Kondo E, Takeda Y, Miyamoto H, Kawaoka Y, Ueda N, Iwata E, Nakahara H, Kobayashi M, Soutome S, Yamada SI, Tojyo I, Kojima Y, Umeda M, Fujita S, Kurita H, Shibuya Y, Kirita T, Komori T; Japanese Study Group of Co-operative Dentistry with Medicine (JCDM).

Osteoporos Int. 2019 Jan;30(1):231-239. doi: 10.1007/s00198-018-4746-8. Epub 2018 Nov 7.

PMID:
30406309
38.

A Defect in Influenza A Virus Particle Assembly Specific to Primary Human Macrophages.

Bedi S, Noda T, Kawaoka Y, Ono A.

MBio. 2018 Oct 23;9(5). pii: e01916-18. doi: 10.1128/mBio.01916-18.

39.

Cryo-EM structure of the Ebola virus nucleoprotein-RNA complex at 3.6 Å resolution.

Sugita Y, Matsunami H, Kawaoka Y, Noda T, Wolf M.

Nature. 2018 Nov;563(7729):137-140. doi: 10.1038/s41586-018-0630-0. Epub 2018 Oct 17.

PMID:
30333622
40.

Recurring and Adaptable Binding Motifs in Broadly Neutralizing Antibodies to Influenza Virus Are Encoded on the D3-9 Segment of the Ig Gene.

Wu NC, Yamayoshi S, Ito M, Uraki R, Kawaoka Y, Wilson IA.

Cell Host Microbe. 2018 Oct 10;24(4):569-578.e4. doi: 10.1016/j.chom.2018.09.010.

41.

Differences in the ease with which mutant viruses escape from human monoclonal antibodies against the HA stem of influenza A virus.

Yamayoshi S, Yasuhara A, Ito M, Uraki R, Kawaoka Y.

J Clin Virol. 2018 Nov;108:105-111. doi: 10.1016/j.jcv.2018.09.016. Epub 2018 Sep 26.

PMID:
30292135
42.

The Cellular DExD/H-Box RNA Helicase UAP56 Co-localizes With the Influenza A Virus NS1 Protein.

Chiba S, Hill-Batorski L, Neumann G, Kawaoka Y.

Front Microbiol. 2018 Sep 12;9:2192. doi: 10.3389/fmicb.2018.02192. eCollection 2018.

43.

Effectiveness of Whole, Inactivated, Low Pathogenicity Influenza A(H7N9) Vaccine against Antigenically Distinct, Highly Pathogenic H7N9 Virus.

Hatta M, Zhong G, Chiba S, Lopes TJS, Neumann G, Kawaoka Y.

Emerg Infect Dis. 2018 Oct;24(10):1910-1913. doi: 10.3201/eid2410.180403.

44.

Selection of Antigenically Advanced Variants of Influenza Viruses.

Neumann G, Fan S, Kawaoka Y.

Methods Mol Biol. 2018;1836:461-486. doi: 10.1007/978-1-4939-8678-1_22.

PMID:
30151587
45.

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.

Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJ, Krause TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton DR, Crowe JE Jr, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly MH, Rijal P, Takada A, Townsend AR, Volchkov V, Walker LM, Wang CI, Zeitlin L, Doranz BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye JM; Viral Hemorrhagic Fever Immunotherapeutic Consortium.

Cell. 2018 Aug 9;174(4):938-952.e13. doi: 10.1016/j.cell.2018.07.033.

46.

A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus.

Gunn BM, Yu WH, Karim MM, Brannan JM, Herbert AS, Wec AZ, Halfmann PJ, Fusco ML, Schendel SL, Gangavarapu K, Krause T, Qiu X, He S, Das J, Suscovich TJ, Lai J, Chandran K, Zeitlin L, Crowe JE Jr, Lauffenburger D, Kawaoka Y, Kobinger GP, Andersen KG, Dye JM, Saphire EO, Alter G.

Cell Host Microbe. 2018 Aug 8;24(2):221-233.e5. doi: 10.1016/j.chom.2018.07.009.

47.

Host Factor Nucleoporin 93 Is Involved in the Nuclear Export of Influenza Virus RNA.

Furusawa Y, Yamada S, Kawaoka Y.

Front Microbiol. 2018 Jul 24;9:1675. doi: 10.3389/fmicb.2018.01675. eCollection 2018.

48.

The Induction of IL-1β Secretion Through the NLRP3 Inflammasome During Ebola Virus Infection.

Halfmann P, Hill-Batorski L, Kawaoka Y.

J Infect Dis. 2018 Nov 22;218(suppl_5):S504-S507. doi: 10.1093/infdis/jiy433.

PMID:
30060221
49.

N-Terminal Acetylation by NatB Is Required for the Shutoff Activity of Influenza A Virus PA-X.

Oishi K, Yamayoshi S, Kozuka-Hata H, Oyama M, Kawaoka Y.

Cell Rep. 2018 Jul 24;24(4):851-860. doi: 10.1016/j.celrep.2018.06.078.

50.

Strain-Specific Contribution of Eukaryotic Elongation Factor 1 Gamma to the Translation of Influenza A Virus Proteins.

Sammaibashi S, Yamayoshi S, Kawaoka Y.

Front Microbiol. 2018 Jun 29;9:1446. doi: 10.3389/fmicb.2018.01446. eCollection 2018.

Supplemental Content

Loading ...
Support Center